
Jan 14 (Reuters) - Immunitybio Inc IBRX.O:
SAUDI FDA GRANTS ACCELERATED APPROVAL TO IMMUNITYBIO’S ANKTIVA® FOR NON-MUSCLE INVASIVE BLADDER CANCER WITH CARCINOMA IN-SITU
IMMUNITYBIO- ENROLLMENT IN RANDOMIZED TRIAL OF ANKTIVA IN BCG NAÏVE NMIBC PATIENTS AHEAD OF SCHEDULE WITH FULL ENROLLMENT ANTICIPATED BY Q2 2026
IMMUNITYBIO INC: ANKTIVA BLA SUBMISSION TARGETED BY YEAR-END